Quick Answer
Theravance Biopharma, Inc. reported Research And Development Expense of $37.41 million for the year ending 2025.
- Theravance Biopharma, Inc. showed a decrease of -0.6% in Research And Development Expense from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $25.41 million | Q2 2013: $30.40 million | Q3 2013: $32.30 million | Q1 2014: $41.72 million | Q2 2014: $46.28 million | Q3 2014: $38.32 million | Q1 2015: $36.02 million | Q2 2015: $30.38 million | Q3 2015: $30.37 million | Q1 2016: $35.68 million | Q2 2016: $32.07 million | Q3 2016: $31.95 million | Q1 2017: $40.57 million | Q2 2017: $42.93 million | Q3 2017: $39.34 million | Q1 2018: $47.77 million | Q2 2018: $48.62 million | Q3 2018: $52.69 million | Q1 2019: $53.82 million | Q2 2019: $46.40 million | Q3 2019: $52.01 million | Q1 2020: $66.01 million | Q2 2020: $62.40 million | Q3 2020: $67.37 million | Q1 2021: $67.60 million | Q2 2021: $51.09 million | Q3 2021: $43.74 million | Q1 2022: $23.25 million | Q2 2022: $14.92 million | Q3 2022: $9.87 million | Q1 2023: $14.57 million | Q2 2023: $9.43 million | Q3 2023: $8.31 million | Q1 2024: $8.97 million | Q2 2024: $9.95 million | Q3 2024: $9.27 million | Q1 2025: $11.45 million | Q2 2025: $10.49 million | Q3 2025: $8.11 million.
- Over the full 14 years of available data (2012 to 2025), Theravance Biopharma, Inc.'s Research And Development Expense has declined by 67.2%.
- Historical annual values: Fiscal year 2025: $37.41 million | Fiscal year 2024: $37.64 million | Fiscal year 2023: $40.62 million | Fiscal year 2022: $63.39 million | Fiscal year 2021: $193.66 million | Fiscal year 2020: $260.95 million | Fiscal year 2019: $219.25 million | Fiscal year 2018: $201.35 million | Fiscal year 2017: $173.89 million | Fiscal year 2016: $141.71 million | Fiscal year 2015: $129.17 million | Fiscal year 2014: $168.52 million | Fiscal year 2013: $120.58 million | Fiscal year 2012: $114.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: